Terrance P. Coyne, who serves as Executive Vice President and Chief Financial Officer of Royalty Pharma plc (NASDAQ:RPRX), executed a sale of 69,582 Class A ordinary shares of the company on January 20, 2026. The transactions produced proceeds of approximately $2.7 million and were carried out at a weighted average price of $39.3484 per share.
The share sales occurred across several transactions, with trade prices ranging from $38.86 to $39.66. Coyne's sales were conducted under a pre-arranged trading arrangement - a 10b5-1 plan - that the executive adopted on August 8, 2025.
Breakdown of the dispositions shows that 65,832 shares were sold indirectly through By TPC RP 2021, LLC, while a further 3,750 shares were sold indirectly through TPC RP EPA1 LLC.
Following these transactions, Coyne's remaining holdings are detailed as follows: 394,996 shares indirectly held through By TPC RP 2021, LLC; 36,010 shares indirectly held through TPC RP EPA1 LLC; 24,170 shares held through Spouse's IRA; 23,270 shares held through an IRA; 1,500 shares held directly; and 1,450 shares held indirectly through Spouse.
Separately, Royalty Pharma reported a robust year for the royalty funding market in 2025. The company said the market reached a record high of $10 billion, and that Royalty Pharma itself accounted for $4.7 billion in announced transactions, representing a 40% share of that activity.
On the shareholder-return front, Royalty Pharma increased its quarterly dividend by 6.8% to $0.235 per Class A ordinary share for the first quarter of 2026.
The company also completed strategic royalty acquisitions. Royalty Pharma acquired the final portion of PTC Therapeutics' remaining royalty on Roche's spinal muscular atrophy treatment Evrysdi for $240 million upfront. The deal includes potential additional contingent payments of up to $60 million tied to sales milestones. This transaction gives Royalty Pharma full ownership of the tiered royalty structure on Evrysdi, which ranges from 8% to 16% of worldwide net sales.
In addition, the company purchased royalty rights to two oncology therapies - neladalkib and zidesamtinib - for up to $315 million. Those assets are described as therapies targeting specific mutations of non-small cell lung cancer. Royalty Pharma characterized these moves as part of its strategy to expand royalty interests across multiple therapeutic areas.
The details of Coyne's sale, the company's dividend action, and the disclosed acquisition terms provide a snapshot of recent insider activity and corporate strategy at Royalty Pharma as it positions itself amid elevated royalty funding market activity.